Cargando…
Failure of Anticoagulation to Prevent Stroke in Context of Lupus-Associated Anti-Phospholipid Syndrome and Mild COVID-19
Hypercoagulability and virally-mediated vascular inflammation have become well-recognized features of the SARS-CoV-2 virus infection, COVID-19. Of growing concern is the apparent ineffectiveness of therapeutic anticoagulation in preventing thromboembolic events among some at-risk patient subtypes wi...
Autores principales: | Kincaid, Keith J., Simpkins, Alexis N. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8041145/ https://www.ncbi.nlm.nih.gov/pubmed/33933349 http://dx.doi.org/10.1016/j.jstrokecerebrovasdis.2021.105817 |
Ejemplares similares
-
Cases of catastrophic anti-phospholipid syndrome in systemic lupus erythematosus: An experience
por: Hegde, Arun, et al.
Publicado: (2022) -
Autoimmune polyendocrine syndrome type 4 with systemic lupus erythematosus and anti-phospholipid syndrome
por: Wang, Yu, et al.
Publicado: (2020) -
Anticoagulants for stroke prevention in heart failure with reduced ejection fraction
por: Schäfer, Andreas, et al.
Publicado: (2021) -
Cognitive Impairment in Anti-Phospholipid Syndrome and Anti-Phospholipid Antibody Carriers
por: Hassan, Fadi, et al.
Publicado: (2022) -
Recent Advances in Anticoagulant Treatment of Immune Thrombosis: A Focus on Direct Oral Anticoagulants in Heparin-Induced Thrombocytopenia and Anti-Phospholipid Syndrome
por: Carré, Julie, et al.
Publicado: (2021)